Next MCL-1 NX232-108-172-001 to#3 exploratory TOX study in dogs admin MCL-1 inhibitor orally, 8/1/17-6/30/19, pre-clin TOX & pharm study of drug DEV for cancer & other diseases, HHSN2612016000161I…
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
Battelle Memorial Institute UEI ZFX8JGFQ89F4 Part of Battelle Memorial Institute
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $116,039
Award facts
- Opportunity
-
- N02CM4700142 Solicitation number
- Preclinical toxicology of drugs developed for cancer patients Award Notice · Posted Apr 4, 2014
- Contract value 100% obligated
- $116,039.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Columbus, OH 43201, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute issued a delivery order to Battelle Memorial Institute on August 11, 2017, under the Toxicology of Drugs Developed for Cancer Patients indefinite delivery contract, with a ceiling value of $116,039.00.
The order calls for an exploratory toxicology study in dogs examining an MCL-1 inhibitor administered orally, supporting preclinical toxicology and pharmacology evaluation of a drug candidate for cancer and other diseases. Place of performance is Columbus, OH. The order's period of performance extends from August 1, 2017, through June 30, 2019, with an ultimate completion date of June 30, 2021. Pricing is cost plus fixed fee.
Description
Next MCL-1 NX232-108-172-001 to#3 exploratory TOX study in dogs admin MCL-1 inhibitor orally, 8/1/17-6/30/19, pre-clin TOX & pharm study of drug DEV for cancer & other diseases, HHSN2612016000161I DTP-17-042 TPB
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to Battelle Memorial Institute by National Cancer Institute (National Institutes of Health) on August 11, 2017.
How much is contract HHSN26100003 worth?
The government has obligated $116,039 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201600016I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award